Trial
NCT02605616
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
AstraZeneca
Condition
Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention
AZ compound
Why stopped
Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-01